## DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Form Approved: OMB No. 0910-0396 Expiration Date: February 28, 2006

## DISCLOSURE: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS

TO BE COMPLETED BY APPLICANT	
The following information concerning, who p	ar-
ticipated as a clinical investigator in the submitted study	
Name	of
, is submitted in accordance with 21 CFR particular study	art
54. The named individual has participated in financial arrangements or holds financial interests to are required to be disclosed as follows:	hat
Please mark the applicable checkboxes.	
any financial arrangement entered into between the sponsor of the covered study and clinical investigator involved in the conduct of the covered study, whereby the value of compensation to the clinical investigator for conducting the study could be influenced by outcome of the study;	the
any significant payments of other sorts made on or after February 2, 1999 from the sponsor the covered study such as a grant to fund ongoing research, compensation in the form equipment, retainer for ongoing consultation, or honoraria;	
any proprietary interest in the product tested in the covered study held by the clini investigator;	cal
any significant equity interest as defined in 21 CFR 54.2(b), held by the clinical investigator the sponsor of the covered study.	r in
Details of the individual's disclosable financial arrangements and interests are attached, along was a description of steps taken to minimize the potential bias of clinical study results by any of disclosed arrangements or interests.	
NAME TITLE	
FIRM/ORGANIZATION	
SIGNATURE DATE	

## **Paperwork Reduction Act Statement**

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 4 hours per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to:

Department of Health and Human Services Food and Drug Administration 5600 Fishers Lane, Room 14-72 Rockville, MD 20857